JCO Global Oncology最新文献

{"title":"Genetic Signatures: <i>CD44</i> Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma.","authors":"Muhammad Kashif, Shah Jahan, Sadia Minhas, Ali Amar, Romeeza Tahir, Haseeb Nisar, Faheem Shehzad, Abdul Hanan Nagi, Nadeem Afzal","doi":"10.1200/GO.24.00084","DOIUrl":"10.1200/GO.24.00084","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the impact of single-nucleotide polymorphisms (SNPs) in the <i>CD44</i> gene, specifically in the 3'UTR region (rs13347) and intronic region (rs187115), on the cell surface expression of CD44 protein and the risk of development of head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Materials and methods: </strong>The study involved analysis of 85 samples and 85 healthy controls. Immunohistochemistry (IHC) and flow cytometry were used to assess cell surface protein expression using CD44 antibody. DNA from formalin-fixed paraffin-embedded tissue sections was isolated and amplified using targeted primers. Sanger sequencing of the resultant amplified products was performed to determine the genotypes of the <i>CD44</i> rs13347 and rs187115 SNPs. GTEx and RegulomeDB were queried to evaluate the genotypic effects of these variants on target gene expression and regulation.</p><p><strong>Results: </strong>A comparison between patients with HNSCC and healthy controls revealed a significant association between <i>CD44</i> rs13347 and an increased risk of HNSCC in all the analyzed models, especially the TT genotype showed a significantly higher risk with an odds ratio of 8.69 (95% CI, 2.35 to 32.09; <i>P</i> = .0003). However, no significant association was found between <i>CD44</i> rs187115 and HNSCC in any of the models analyzed (all <i>P</i> > .05). Other notable findings included significant associations between <i>CD44</i> rs13347 genotype and age (<i>P</i> = .031), number of CD44-positive tumor cells (<i>P</i> = .049), CD44 staining intensity (SI; <i>P</i> = .039), and CD44 immunoreactivity score (IRS) status (<i>P</i> = .019).</p><p><strong>Conclusion: </strong>The T allele and homozygous TT genotype of <i>CD44</i> rs13347 SNP were associated with increased susceptibility to HNSCC and decreased proportion of CD44-positive tumor cells, low SI, and reduced IRS.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400084"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Clinicopathologic Characteristics and Survival Rates of Colorectal Cancer Among Syrian Refugees and Turkish Population in Gaziantep Province.","authors":"Canan Karan, İlker Nihat Okten, Oğuzhan Kesen, Atalay Çelikyürek, Fatih Teker, Şuayib Yalçın","doi":"10.1200/GO.24.00211","DOIUrl":"10.1200/GO.24.00211","url":null,"abstract":"<p><strong>Purpose: </strong>Syrian refugees (SRs) have had difficulties in the diagnosis, treatment, and follow-up of chronic diseases, such as cancer, because of the conflict in the region. The cancer diagnosis and treatment process of SR are also a matter of curiosity. We aimed to compare the demographic characteristics and survival outcome data of SRs and Turkish citizens (TCs), and colorectal cancer (CRC) is one of the most common cancer types seen with similar frequency globally.</p><p><strong>Materials and methods: </strong>A total of 421 patients with CRC were included. Overall survival (OS) was estimated using the Kaplan-Meier method, and the log-rank test was used for comparison. Patient demographic data were compared using the Pearson Chi-square test and independent <i>t</i> test.</p><p><strong>Results: </strong>In total, 421 patients (282 TCs and 139 SRs) were included in this study. The mean age was 52.9 ± 14.3 years for the entire population: 55.3 ± 14.1 years for TCs and 47.9 ± 13.4 years for SRs. Forty (29%) SRs and 60 (21.4%) TCs had de novo metastatic disease (<i>P</i> = .08). The median OS in the general population was 57.9 months (95% CI, 40.1 to 75.7), whereas it was 80.9 months (95% CI, 56.5 to 97.2) in TCs and 42.2 months in SRs (95% CI, 27.0 to 57.4; <i>P</i> = .006). In the nonmetastatic group, the median OS did not reach (NR) in TCs, and it was 52.6 months (95% CI, 43.7 to 61.5) in SRs (<i>P</i> = .02). In the metastatic group, the median OS was 21 months (95% CI, 8.5 to 29.2) in TCs, and it was 18.9 months in SRs (95% CI, 16.3 to 25.7; <i>P</i> = .93).</p><p><strong>Conclusion: </strong>The survival rate was lower in the SR group. Since CRC is also common among refugees, developing and implementing methods to improve the welfare of vulnerable populations is necessary.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400211"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Cancer Supportive Care: Integrating Psychosocial Support, Nutrition, and Physical Activity Using Telehealth Solutions.","authors":"Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip, Renata Ferrari, Rafaela Mota Peixoto, Tracy E Crane, Kathryn H Schmitz, Enrique Soto-Perez-de-Celis","doi":"10.1200/GO-24-00333","DOIUrl":"10.1200/GO-24-00333","url":null,"abstract":"<p><p>This review explores current guidelines for integrating psychosocial support, nutrition, and physical activity into cancer care and examines the resources available to deliver comprehensive care effectively and equitably, with a focus on telehealth solutions. A review of current guidelines related to psychosocial support, nutrition, and exercise in oncology published between the years 2020 and 2024 was conducted. Additionally, relevant articles from the authors' personal archives were included. Current guidelines emphasize routine psychosocial distress screening, nutritional assessment, and tailored physical activity interventions for patients with cancer. The National Comprehensive Cancer Network and ASCO highlight the need for regular psychosocial evaluations and the management of common psychiatric disorders. The American Cancer Society and the Academy of Nutrition and Dietetics recommend nutritional screening, personalized counseling, and exercise to improve treatment tolerance and overall quality of life. Despite these recommendations, challenges such as resource limitations, time constraints, and financial barriers hinder their implementation. Integrating psychosocial support, medical nutrition therapy, and physical activity into cancer care is essential to enhancing patients' quality of life. Telehealth offers a viable solution to overcome barriers by providing remote access to supportive services, facilitating comprehensive care, and promoting patient engagement. The effectiveness of telehealth in delivering psychosocial, nutritional, and physical activity support highlights its potential to improve patient outcomes and overcome barriers to care. Telehealth technologies hold high potential to optimize cancer care delivery, ensuring personalized support for patients throughout their cancer journey.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400333"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delays in Presentation, Diagnosis, and Treatment Among Patients With GI Cancer in Southwest Nigeria.","authors":"Justina Ucheojor Onwuka, Funmilola Olanike Wuraola, Israel Adeyemi Owoade, Yetunde Florence Ogunyemi, Matteo Di Bernardo, Anna J Dare, Tajudeen Olakunle Mohammed, Mahdi Sheikh, Olalekan Olasehinde, T Peter Kingham, Hilary A Robbins, Olusegun Isaac Alatise","doi":"10.1200/GO.24.00060","DOIUrl":"10.1200/GO.24.00060","url":null,"abstract":"<p><strong>Purpose: </strong>The incidence of GI cancers is increasing in sub-Saharan African countries. We described the oncological care pathway and assessed presentation, diagnosis, and treatment intervals and delays among patients with GI cancer who presented to the Obafemi Awolowo University Teaching Hospitals Complex in Ile-Ife, Nigeria.</p><p><strong>Methods: </strong>We analyzed data from 545 patients with GI cancer in the African Research Group for Oncology (ARGO) database. We defined presentation interval as the interval between symptom onset and presentation to tertiary hospital, diagnostic interval as between presentation and diagnosis, and treatment interval as between diagnosis and initiation of treatment. We considered >3 months, >1 month, and >1 month to be presentation, diagnosis, and treatment delays, respectively. We compared lengths of intervals using Mann-Whitney <i>U</i> tests and logistic regression.</p><p><strong>Results: </strong>The most frequent cancer types were pancreatic (32%) and colorectal (28%). Most patients presented at stages III (38%) and IV (30%). The median presentation interval was 84 days (IQR, 56-191), and 49% presented after 3 months or longer. The median diagnosis and treatment intervals were 0 (IQR, 0-8) and 7 (IQR, 0-23) days, respectively. There was no relationship between age, sex, education, or distance to tertiary hospital and presentation delay, but patients with stage III to IV versus I to II had higher odds of presentation delay (odds ratio [OR], 1.68 [95% CI, 1.13 to 2.50]). Among patients with pancreatic cancer, older patients were less likely to have a diagnosis delay (OR, 0.50 [95% CI, 0.25 to 0.98]).</p><p><strong>Conclusion: </strong>About half of patients with GI cancer in Ile-Ife, Nigeria, did not present to tertiary hospitals until more than 90 days after noticing symptoms. Efforts are warranted to improve public knowledge of GI cancer symptoms and to strengthen health systems for prompt diagnosis and referral to specialty care.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400060"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to P. Boffetta and M. Seyyedsalehi.","authors":"Thilagavathi Ramamoorthy, Anita Nath, Shubhra Singh, Stany Mathew, Apourv Pant, Samvedana Sheela, Gurpreet Kaur, Krishnan Sathishkumar, Prashant Mathur","doi":"10.1200/GO-24-00460","DOIUrl":"10.1200/GO-24-00460","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400460"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Impact of Cancer Across the Intergenerational Family: A Multidimensional Perspective From African Countries.","authors":"","doi":"10.1200/GO-24-00517","DOIUrl":"10.1200/GO-24-00517","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400517"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer and Risk of Depression: A Comparative Cross-Sectional Study Among Women With and Without Breast Cancer in Addis Ababa, Ethiopia.","authors":"Alem Gebremariam, Adamu Addissie, Nebiyu Dereje, Mathewos Assefa, Ahmedin Jemal","doi":"10.1200/GO.24.00235","DOIUrl":"10.1200/GO.24.00235","url":null,"abstract":"<p><strong>Purpose: </strong>The extent of symptoms of depression among patients with breast cancer compared with those without the disease is not well documented in Ethiopia and other sub-Saharan African countries.</p><p><strong>Materials and methods: </strong>This study examines the prevalence of symptoms of depression in women with breast cancer (n = 436) compared with those without breast cancer (n = 856) in Addis Ababa, Ethiopia, through a comparative cross-sectional study using a validated questionnaire, the Patient Health Questionnaire-9. The association between breast cancer diagnosis and symptoms of depression was evaluated using a multivariable binary logistic regression model.</p><p><strong>Results: </strong>About 39.2% of women with breast cancer had some level of symptoms of depression compared with 23.8% of women without the disease. By severity of symptoms of depression, 13.1% of women with breast cancer reported moderate to severe symptoms of depression compared with 6.8% of women without the disease. Sixty-three percent of women with breast cancer reported difficulties performing routine daily activities, compared with 36.7% of women without the disease. In the multivariable-adjusted model, women with breast cancer were 2 times (adjusted odds ratio, 2.26 [95% CI, 1.49 to 3.44]) more likely to report symptoms of depression compared with those without the disease. Likewise, women with breast cancer were 4.78 (95% CI, 3.51 to 6.52) times more likely to report difficulty in performing routine daily activities compared with women without the disease.</p><p><strong>Conclusion: </strong>Four in 10 women with breast cancer in Addis Ababa reported having symptoms of depression, which was considerably higher than women in the general population. This finding emphasizes the importance of addressing psychosocial needs among women with breast cancer to enhance quality of life and potentially extend longevity.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400235"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Risk Score for Invasive Nonmetastatic Breast Cancer: A Real-World Analysis.","authors":"Lucia Mangone, Fortunato Morabito, Giovanni Tripepi, Graziella D'Arrigo, Santina Maria Grazia Romeo, Isabella Bisceglia, Maria Barbara Braghiroli, Francesco Marinelli, Giancarlo Bisagni, Antonino Neri, Carmine Pinto","doi":"10.1200/GO.23.00390","DOIUrl":"10.1200/GO.23.00390","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to develop a multivariable, weighted overall survival (OS) risk score (SRS) for nonmetastatic (M0) invasive breast cancer (M0-BC, SRS_M0-BC).</p><p><strong>Materials and methods: </strong>This study included a training (1,890 patients) and a validation cohort (850 patients) from the Reggio Emilia Cancer Registry (RE-CR). Ten traditional prognostic variables were evaluated.</p><p><strong>Results: </strong>In the training set, all the variables but the human epidermal growth factor receptor were significantly associated with OS at univariable analysis. A multivariable model identified an increased death risk for estrogen receptor (hazard ratio [HR], 2.0 [95% CI, 1.1 to 3.1]; <i>P</i> = .021), tumor stages T2-T3 (HR, 2.4 [95% CI, 1.3 to 4.7]; <i>P</i> = .009) and T4 (HR, 5.1 [95% CI, 2.0 to 13.0]; <i>P</i> < .001), and age >74 years (HR, 5.7 [95% CI, 4.0 to 8.2]; <i>P</i> < .001). By assigning scores according to HRs, four risk categories were generated (<i>P</i> for trend <.001). The HRs of death in the high- (282 patients, 15.6%), intermediate-high (275 patients, 15.2%), and intermediate-risk (349 patients, 19.2%) categories patients were, respectively, 27.3, 12.9, and 3.5 times higher, compared with the low-risk (909 patients, 50%) group. Harrell'C index was 81.1%, and the explained variation in mortality was 66.6. Internal cross-validation performed on the accrual index dates yielded a Harrell'C index ranging from 79.5% to 82.3% and an explained variation in mortality ranging from 60.3% to 69.4%. In the validation set, the same risk categories (<i>P</i> for trend <.001) were devised. The Harrell'C index and the explained variation in mortality were 76.1% and 53.7%, respectively, in the whole cohort, maintaining an elevated percentage according to the two accrual index dates.</p><p><strong>Conclusion: </strong>SRS_M0-BC using the real-world RE-CR data set may represent a low-cost, accessible, globally applicable model in daily clinical practice, helping to prognostically stratify patients with invasive M0-BC.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2300390"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collecting Long-Term Outcomes in Population-Based Cancer Registry Data: The Case of Breast Cancer Recurrence.","authors":"Eileen Morgan, Colette O'Neill, Aude Bardot, Paul Walsh, Ryan R Woods, Lou Gonsalves, Sinéad Hawkins, Jan F Nygård, Serban Negoita, Esmeralda Ramirez-Pena, Karen Gelmon, Sabine Siesling, Fatima Cardoso, Julie Gralow, Isabelle Soerjomataram, Melina Arnold","doi":"10.1200/GO-24-00249","DOIUrl":"10.1200/GO-24-00249","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer recurrence is an important long-term outcome of cancer survivors that is often not routinely collected and recorded by population-based registries. In this study, we review population-based studies to determine the current availability, landscape, and infrastructure of long-term outcomes, particularly metastatic recurrence, in women initially diagnosed with nonmetastatic breast cancer (MBC).</p><p><strong>Methods: </strong>We reviewed the literature to identify studies that used population-based registry data to examine the distribution of metastatic recurrence in women diagnosed with non-MBC. Data on outcomes and methods of ascertainment were extracted. Registry infrastructure including sources and funding was also reviewed.</p><p><strong>Results: </strong>A total of 23 studies from 11 registries in eight countries spanning Europe, North America, and Oceania were identified and included in the review. Most studies were retrospective in nature and collected recurrence data only for ad hoc studies rather than as part of their routine registration. Definition of recurrence and data sources varied considerably across studies: the cancer-free time interval between the start of follow-up and risk window ranged from the diagnosis of primary tumor (n = 7) to 6 months from diagnosis (n = 1); the start of follow-up differed between initial diagnosis (n = 16) and treatment (n = 7).</p><p><strong>Conclusion: </strong>Cancer surveillance should encompass outcomes among survivors for research and monitoring. Studies are underway, but more are needed. Cancer registries should be supported to routinely collect recurrence data to allow complete evaluation of MBC as an outcome to be conducted and inform health care providers and researchers of the prognosis of both nonmetastatic and metastatic patients with breast cancer.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400249"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Global Impact of Ambient Air Pollution on Cancer Incidence and Mortality: A Comprehensive Meta-Analysis.","authors":"Paolo Boffetta, Monireh Sadat Seyyedsalehi","doi":"10.1200/GO-24-00402","DOIUrl":"10.1200/GO-24-00402","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400402"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}